TRxADE Health appoints Jeff Newell to Board of Directors, effective Sept 30, 2022

Scienture Holdings, Inc.

Jeff Newell appointed to fill board vacancy left by Christine L. Jennings' Aug 26 resignation.
Newell joins Audit, Compensation, and Nominating/Governance committees.
Previously served on Advisory Board for $3,000/month; consulting agreement terminated upon appointment.
Newell brings over 40 years healthcare experience, including CEO at Pharmacy Quality Solutions and Kmart Pharmacy.
Board now has majority independent directors and fully constituted three-member Audit Committee.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeff Newell

Director

SCNX · Scienture Holdings, Inc.

Effective: 2022-09-30
Filed: October 3, 2022, 7:59 PM ET

On September 30, 2022, the Board of Directors of TRxADE HEALTH, INC. (“ TRxADE ”, the “ Company ”, “ we ” and “ us ”), with the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors, appointed Mr. Jeff Newell as a member of the Board of Directors, with such appointment to take effect immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeff Newell was appointed as Director at Scienture Holdings, Inc..

Action: appointed
Role: Director

Exact text from the filing

On September 30, 2022, the Board of Directors of TRxADE HEALTH, INC. (“ TRxADE ”, the “ Company ”, “ we ” and “ us ”), with the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors, appointed Mr. Jeff Newell as a member of the Board of Directors, with such appointment to take effect immediately.

View on SEC.gov

Scienture Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-027358

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.